Stereotaxis Ord Stock Price, News & Analysis

Stereotaxis (NYSE: STXS) reported a 6% year-over-year revenue increase to $8.7 million for Q3 2020, attributed to the installation of its Genesis RMN® Systems in the US and Europe. The system revenue was $3.0 million, while recurring revenue decreased to $5.5 million from $6.3 million due to a 10% decline in procedure volumes linked to COVID-19 impacts. The company anticipates $10-20 million in Genesis system revenue for 2021 and plans initial commercialization of a new robotic catheter. Operating loss was $1.6 million, with a cash balance of $43.8 million as of September 30, 2020.

Stereotaxis (NYSE: STXS) announces the release of its third quarter financial results on November 9, 2020, before U.S. market opening. The company will also host a conference call at 10:00 a.m. ET to discuss the results and corporate developments. Investors can access the call by dialing 800-437-2398 (US/Canada) or 856-344-9206 (International) with the pass code 9232669. A replay will be available for one week after the call. Stereotaxis is a leader in robotic technologies for cardiac arrhythmia treatment.

Stereotaxis (STXS) announced the installation of the Genesis Robotic Magnetic Navigation (RMN) systems at Helsinki University Hospital and Banner - University Medicine Heart Institute, the world’s first implementations aimed at treating heart rhythm disorders. These advanced robotic systems enhance precision in cardiac ablation procedures, addressing the growing need for effective solutions for arrhythmias, which can lead to serious health risks. The technology is expected to provide a competitive edge for both institutions in patient care and education in the field.

Stereotaxis (NYSE: STXS) announced that Chairman and CEO David Fischel will speak at RAPS Convergence 2020, the largest annual gathering of healthcare regulatory professionals, on September 13, 2020. Fischel will discuss how regulatory professionals can enhance medical innovation and healthcare access through interoperability and open standards. He emphasized the critical role that regulatory experts play in advancing healthcare innovation. Stereotaxis is known for its robotic technologies that improve arrhythmia treatment. For more information, visit www.stereotaxis.com.

Stereotaxis (NYSE: STXS), a leader in robotic technologies for cardiac arrhythmia treatment, announced CEO David Fischel will present at three investor conferences in September 2020. The presentations include the LD Micro 500 on September 4, Cantor Fitzgerald Global Healthcare on September 15, and Lake Street Best Ideas Growth on September 17, where one-on-one meetings will be available. Fischel aims to share insights on Stereotaxis’ technology and growth strategy, underlining the company’s commitment to enhancing patient care.

Stereotaxis (NYSE: STXS) announced a significant publication in the Journal of the American College of Cardiology, highlighting a study on robotic technology for treating chronic thromboembolic pulmonary hypertension (CTEPH). The trial, involving 50 patients, demonstrated that robotic magnetic navigation enhanced outcomes, with pulmonary vascular resistance improving significantly (p=0.001) and an 86% reduction in heart failure-related hospitalizations (p=0.049) at 12 months. This advancement in robotic technology presents a promising new therapy for pulmonary hypertension, revealing its potential beyond arrhythmias.

Stereotaxis (STXS) reported a 21% decline in second-quarter revenue, totaling $5.3 million, primarily due to a 38% drop in procedure volumes amid COVID-19 challenges. Despite this setback, the company achieved notable milestones, including the installation of the first Genesis RMN® System and advancements in its robotically-navigated ablation catheter. Operating expenses decreased 13% to $6.2 million, demonstrating prudent management. As of June 30, 2020, Stereotaxis held a cash balance of $44 million, positioning it strongly for future growth.

Stereotaxis (NYSE: STXS) and Acutus Medical have successfully conducted the first integrated cardiac ablation procedure utilizing remote TeleRobotic Support. Dr. Gery Tomassoni performed the procedure at Baptist Health in Lexington, KY, combining Stereotaxis Robotic Magnetic Navigation and Acutus' AcQMap systems. This innovative integration enhances the accuracy of arrhythmia treatment through high-resolution imaging and robotic navigation. The TeleRobotic capabilities allow real-time support from experts, improving patient care while minimizing surgical risks.

Stereotaxis (STXS) announced it will release its financial results for Q2 2020 on August 6, 2020, prior to the U.S. market opening. A conference call will follow at 10:00 a.m. ET to discuss the results and corporate developments. Investors can access the call via phone or webcast. Stereotaxis specializes in robotic technologies for treating cardiac arrhythmias, and its systems are approved in several major markets including the U.S., EU, and Japan.